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Association between localised 
retinal nerve fibre layer defects and 
cardiovascular risk factors
Joo Youn Shin1,2, Jonghyun Lee1, Chan Joo Lee3,4, Sungha park4 & Suk Ho  Byeon2*
Localised retinal nerve fibre layer defects (RNFLDs) are reported to indicate the degree of glaucomatous 
damage but can also be sequelae of retinal vascular insufficiency as a result of systemic vascular factors. 
We investigated the association between RNFLDs and cardiovascular risk factors. RNFLDs were 
detected in 440 (29.2%) of 1508 subjects. The presence of RNFLDs was associated with higher HbA1c 
(odds ratio [OR] 1.289, p < 0.001), higher 24-h mean systolic blood pressure (SBP; OR 1.013, p < 0.005), 
and lower estimated glomerular filtration rate (eGFR; OR 0.995, p < 0.005). An increasing number of 
RNFLDs was correlated with higher SBP (r = 0.186, p < 0.001), higher HbA1c (r = 0.128, p < 0.010), lower 
eGFR (r = −0.112, p < 0.020), and younger age (r = −0.303, p < 0.001). Subjects with RNFLDs had a 
higher predicted 10-year risk of atherosclerotic cardiovascular disease than did those without RNFLDs 
(9.7% vs 7.9%, p = 0.008 in middle-aged subjects, 25.6% vs 23.2%, p = 0.040 in older subjects). In 
conclusion, RNFLDs are associated with SBP, eGFR, and HbA1c. Concomitant cardiovascular risk factors 
should be considered when evaluating patients with localised RNFLDs.
Localised retinal nerve fibre layer defects (RNFLDs) have been reported to be a sensitive indicator of the degree of 
glaucomatous damage in patients with glaucomatous optic neuropathy1. However, these defects are not pathog-
nomonic of glaucoma and can also be sequelae of retinal vascular insufficiency2. In an experiment in rhesus 
monkeys, chronic arterial hypertension and atherosclerosis were reported to lead to localised RNFLDs without 
glaucomatous changes in the neuroretinal rim or peripapillary atrophy3. Localised RNFLDs can also develop 
after appearance of retinal cotton-wool spots in patients with systemic hypertension or diabetes mellitus (DM)2,4.
Previous studies have suggested an association between localised RNFLDs and risk factors for cardiovascular 
disease, including high blood pressure (BP) and diabetes5,6. Localised RNFLDs have also been reported to be 
associated with cerebral small vessel disease and stroke7,8, suggesting that these lesions are potential biomarkers 
of cardiovascular risk. However, most of the studies performed to date have analysed a limited number of subjects 
or have not fully evaluated the various systemic factors.
The Cardiovascular and Metabolic Disease Etiology Research Center-High Risk Cohort (CMERC-HI) study 
is a prospective cohort investigation of the value of known and novel predictors of clinical outcomes in subjects 
at risk of cardiovascular disease. The aim of the present study was to evaluate the association between localised 
RNFLDs and various cardiovascular risk factors using the baseline CMERC-HI data to improve understanding 
of the pathogenesis of RNFLDs.
Results
Subject characteristics at baseline. Localised RNFLDs were detected in 440 (29.2%) of the 1508 subjects 
(Table 1). Subjects with RNFLDs had a higher glycated haemoglobin (HbA1c) level (p = 0.003), higher BP (mean 
24-h systolic BP [SBP] and diastolic BP [DBP], daytime SBP, night-time SBP and DBP [p < 0.001], and day-
time DBP [p = 0.007]) and a lower estimated glomerular filtration rate (eGFR; p < 0.001) than did those without 
RNFLDs. There was no difference in age (p = 0.131), sex (p = 0.424), rate of hypertension (p = 0.968), rate of DM 
(p = 0.102), lipid profile values, or urinary albumin to creatinine ratio between the two groups.
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Association between RNFLDs and cardiovascular risk factors. In the regression analysis, local-
ised RNFLDs was the dependent variable and other parameters that were significantly associated with localised 
RNFLDs in the univariate analysis (Table 1) and were clinically significant were the independent variables. In the 
multivariate logistic regression, higher HbA1c (odds ratio [OR] 1.289, 95% confidence interval [CI] 1.13–1.47, 
p < 0.001), higher 24-h mean SBP (OR 1.013, 95% CI 1.004–1.022, p = 0.005), and lower eGFR (OR 0.995, 95% CI 
0.991–0.998, p = 0.005; Table 2) were found to be associated with the presence of localised RNFLDs.
Given the association of presence of localised RNFLDs with higher HbA1c, we performed regression analysis 
by dividing the subjects into a diabetes group and a non-diabetes group. In the non-diabetes group, the presence 
of localised RNFLDs was associated with a higher 24-h mean SBP (OR 1.013, 95% CI 1.002–1.024, p = 0.024) 
and a lower eGFR (OR 0.994, 95% CI 0.989–0.998, p = 0.007) after adjustment for age, sex, and body mass index 
(BMI). In the diabetes group, the presence of RNFLDs was significantly associated with a higher HbA1c (OR 
1.446, 95% CI 1.195–1.749, p < 0.001) and a higher 24-h mean SBP (OR 1.014, 95% CI 1.0–−1.028, p = 0.045) 
after adjustment for age, sex, BMI, and eGFR (OR 0.994, 95% CI 0.988–1.00, p = 0.057, for eGFR).
Correlation between number of RNFLDs and cardiovascular risk factors. As with the presence 
of RNFLDs, the number of RNFLDs was significantly correlated with higher HbA1c (r = 0.128, p = 0.010), 
higher mean 24-h SBP (r = 0.186, p < 0.001), and lower eGFR (r = −0.112, p = 0.020). The increasing number of 
RNFLDs was also correlated with younger age (r = −0.303, p < 0.001). No correlation was detected between the 
number of RNFLDs and sex (p = 0.924) or BMI (p = 0.972; Table 3).
Predicted 10-year risk of atherosclerotic cardiovascular disease. Six hundred and twenty-three 
subjects were aged 40–59 years (designated the middle-aged group) and 781 were aged 60–79 years (designated 
the older group). RNFLDs were observed in 31.5% of the middle-aged group and 26.9% of the older group. The 
mean ASCVD risk score for subjects with RNFLDs was 9.7% in the middle-aged group and 25.6% in the older 
group; the score was significantly higher in subjects with RNFLDs than in those without RNFLDs in both age 
groups (p = 0.008 and p = 0.040, respectively, Table 4).
Variable RNFLD (−) RNFLD (+) p-value
Subjects, n 1068 440
Age, years 59.76 ± 11.55 58.76 ± 11.80 0.131
Sex, male, n (%) 594 (55) 255 (58) 0.424
BMI 25.31 ± 3.62 25.08 ± 3.79 0.234
Smoking status
Never/Past/Current, n 580/ 349/ 139 231/150/59 0.813
Hypertension, n (%) 997 (93) 411 (93) 0.968
24-h ambulatory BP monitoring
 24-h SBP, mmHg 129.16 ± 14.21 133.64 ± 15.35 <0.001*
 24-h DBP, mmHg 77.80 ± 8.03 79.60 ± 8.63 <0.001*
 Daytime SBP, mmHg 133.84 ± 14.31 137.91 ± 15.21 <0.001*
 Daytime DBP, mmHg 80.93 ± 8.44 82.30 ± 8.87 0.007*
 Night-time SBP, mmHg 120.33 ± 16.43 125.83 ± 18.27 <0.001*
 Night-time DBP, mmHg 71.93 ± 8.87 74.87 ± 10.01 <0.001*
Diabetes
 DM, n (%) 388 (36) 180 (41) 0.102
 HbA1c, % 6.06 ± 0.84 6.25 ± 1.12 0.003*
 Glucose, mg/dL 109.80 ± 26.73 114.82 ± 37.11 0.012*
Kidney function
 BUN, mg/dL 24.01 ± 16.25 28.98 ± 21.49 <0.001*
 Creatinine, mg/dL 1.83 ± 2.46 2.55 ± 3.34 <0.001*
 eGFR, mL/min/1.73 m2 67.35 ± 33.42 58.16 ± 35.56 <0.001*
 Urinary ACR (mg/g) 309.96 ± 788.4 385.7 ± 907.5 0.127
Lipid profile
 Total cholesterol, mg/dL 171.69 ± 36.06 172.43 ± 35.59 0.723
 HDL cholesterol, mg/dL 49.11 ± 13.56 47.55 ± 13.19 0.806
 LDL cholesterol, mg/dL 94.23 ± 29.07 95.09 ± 29.87 0.622
 Triglycerides, mg/dL 138.52 ± 88.12 145.05 ± 79.81 0.199
Table 1. Baseline characteristics according to the presence of localised retinal nerve fibre layer defects. The data 
are shown as the mean ± standard deviation or the number (percentage). *P < 0.05. ACR, albumin to creatinine 
ratio; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular 
filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
RNFLD, localised retinal nerve fibre layer defect; SBP, systolic blood pressure
3Scientific RepoRtS |         (2019) 9:19340  | https://doi.org/10.1038/s41598-019-55846-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
The present study investigated the association between localised RNFLDs and cardiovascular risk factors and 
showed that RNFLDs were associated with 24-h mean SBP, HbA1c, and eGFR values after adjustment. An increas-
ing number of RNFLDs was also correlated with higher SBP, lower eGFR, higher HbA1c, and younger age. The 
10-year predicted risk of cardiovascular disease using the ASCVD score was significantly higher in subjects with 
localised RNFLDs than in those without RNFLDs. Our results suggest that concomitant cardiovascular risk fac-
tors should be considered when evaluating patients with localised RNFLDs.
Localised RNFLDs have been reported to be associated with arterial hypertension5,9,10. Chronic arterial hyper-
tension and atherosclerosis led to development of localised RNFLDs in a rhesus monkey model3, and localised 
RNFLDs were also reported to be associated with increasing grades of arterial hypertension5. The most common 
causes of RNFLDs in patients with uncontrolled hypertension are cotton-wool spots11 and/or hypertensive optic 
neuropathy12. The authors of a study in primates with experimental renovascular hypertension suggested that 
autoregulatory vasoconstriction in the superficial arterioles resulting from high BP leads to occlusive sequelae 
and ischemic damage in the inner retina5,13. Our finding of an association between localised RNFLDs and higher 
BP, i.e., the probability of having RNFLDs increases by 1.13-fold with a 10-mmHg increment in blood pressure, 
is in line with earlier reports.
Analysis of our 24-h ambulatory BP monitoring results revealed that the presence of RNFLDs was associated 
with persistently high SBP and DBP. It has been reported that ambulatory BP provides better prognostic informa-
tion than does BP recorded in the office in patients with cardiovascular disease and that high BP at night increases 
the cardiovascular risk in patients with high ambulatory daytime BP14. Therefore, the finding in our study that 
both daytime and night-time BP values were higher in subjects with RNFLDs than in those without RNFLDs 
suggests an increased likelihood of cardiovascular events, as seen in previous studies that have identified an asso-
ciation between RNFLDs and stroke7,8.
Unit change OR 95% CI P-value
Age Per 1-year increment 0.991 0.98–1.002 0.110
Sex Female vs male 0.950 0.74–1.23 0.695
BMI Per 1-kg/m2 increment 0.974 0.94–1.01 0.144
HbA1c Per 1% increment 1.289 1.13–1.47 <0.001*
Mean 24-h SBP Per 1-mmHg increment 1.013 1.004–1.022 0.005*
eGFR Per 1-mL/min/1.73 m2 increment 0.995 0.991–0.998 0.005*
Table 2. Factors associated with presence of localised retinal nerve fibre layer defects using multivariate logistic 
regression analysis. *p < 0.05. BMI, body mass index; CI, confidence interval; HbA1c, glycated haemoglobin; 
OR, odds ratio; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate.
Variables
RNFLDs, n Pearson’s coefficient
p-value1 2 ≥3
Age (years) 61.8 ± 10.5 57.8 ± 12.0 52.3 ± 11.9 −0.303 <0.001
Sex (M/F) 125/92 84/57 46/36 0.005 0.924
BMI 25.0 ± 3.3 25.2 ± 3.9 25.0 ± 4.6 0.002 0.972
Mean 24-h SBP (mmHg) 131.5 ± 14.4 133.9 ± 14.0 139.5 ± 18.7 0.186 <0.001
HbA1c (%) 6.10 ± 0.85 6.36 ± 1.28 6.45 ± 1.39 0.128 0.010
eGFR (mL/min/1.73 m2) 61.1 ± 34.0 58.7 ± 37.3 49.7 ± 35.5 −0.112 0.020
Table 3. Correlation between number of localised retinal nerve fibre layer defects and cardiovascular risk 
factors. *p < 0.05. RNFLD, retinal nerve fibre layer defect; BMI, body mass index; HbA1c, glycated haemoglobin; 
SBP, mean systolic blood pressure; eGFR, estimated glomerular filtration rate.
Age group n 10-year risk predicted by ASCVD score (%) p-value
40–59 years
RNFLD (−) 427 7.9 ± 7.1
0.008*
RNFLD (+) 196 9.7 ± 8.2
60–79 years
RNFLD (-) 571 23.2 ± 14.5
0.040*
RNFLD (+) 210 25.6 ± 14.6
Table 4. Predicted 10-year risk of ASCVD by ASCVD score according to the presence of localised retinal nerve 
fibre layer defects. *p < 0.05. RNFLD, retinal nerve fibre layer defect; ASCVD, atherosclerotic cardiovascular 
disease.
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The presence of localised RNFLDs was also associated with the HbA1c value. Although the mechanism of 
RNFLDs in subjects with diabetes is not completely understood, oxidative stress, accumulation of advanced glyca-
tion end products, and impaired retrograde axonal transport of ganglion cells have been suggested to play a role2,15,16. 
Acute nonperfusion of the retina causes a blockage of axoplasmic transport and formation of cotton-wool spots, and 
it has been reported that approximately 22% of cotton-wool spots cause clinically visible RNFLDs in patients with 
diabetic retinopathy2. The frequency of these changes was reported to depend on the severity and duration of disease 
and on the BP17. Increased BP has been hypothesised to damage the retinal capillary endothelial cells in patients with 
diabetes18, and our finding that the presence of RNFLDs in subjects with diabetes was also associated with SBP after 
adjustment for HbA1c is consistent with the mechanism proposed in previous studies.
There was an independent association between the presence of RNFLDs and a lower eGFR, particularly in 
subjects without diabetes after adjustment for other cardiovascular risk factors. Pathogenic abnormalities, includ-
ing dysfunction of the renin-angiotensin system, atherosclerosis, and oxidative stress, may occur throughout 
the body; microvascular damage from hypertension, DM, and other processes affecting the retinal and renal 
vasculature may be useful indicators of cumulative damage. Previous studies have shown that the RNFL is thin-
ner in patients who have chronic renal failure without DM19 and in those receiving haemodialysis20 than in the 
normal population. The authors of those studies suggested subclinical ischemic retinopathy as the reason for the 
reduction in retinal thickness in patients with chronic kidney disease. Our result is consistent with their findings 
and suggests that localised RNFLDs could indicate generalised systemic microvascular injury and also reflect 
underlying renal injury21.
As with the presence of RNFLDs, the number of RNFLDs was significantly correlated with cardiovascular 
risk factors including higher SBP, lower eGFR, and higher HbA1c, supporting the notion that RNFLDs could be a 
potential biomarker of cardiovascular risk22. On the other hand, the number of RNFLDs was inversely correlated 
with age. The reason for this result is unclear, but we can speculate about the reason on the basis of the finding in 
a previous study that younger age was a strong independent risk factor for development of grade III/IV hyperten-
sive retinopathy23. Alternatively, this finding could reflect the decreased visibility of localised RNFLDs in older 
individuals8.
Subjects with RNFLDs had a significantly higher predicted 10-year risk for ASCVD than did those without 
RNFLDs regardless of whether they were middle-aged or older. This result suggests that RNFLDs may have a 
predictive value with regard to cardiovascular risk. In particular, given our findings that the number of RNFLDs 
was inversely correlated with age and that the ASCVD risk score in the RNFLD group was more significant in the 
middle-aged group than in the older group, RNFLDs may be of more benefit for prediction of cardiovascular risk 
in younger, middle-aged individuals with risk factors. A longitudinal study will be needed to answer this question.
There are some limitations to our study. We included only subjects of the same ethnicity with a high risk of 
developing cardiovascular disease, so it may be difficult to generalise our findings. Similar studies in the general 
population are now needed. Furthermore, a previous study reported that the ASCVD risk score in the Korean 
population was overestimated by the ACC/AHA risk equations24, so our calculated risk score may not reflect the 
actual risk. We anticipate that the 5–10-year outcomes in our cohort will be needed to determine conclusively 
whether or not evaluation of RNFLDs would be of benefit over and above that of existing methods for prediction 
of cardiovascular risk. The cross-sectional study design and lack of a control group were further limitations. 
Moreover, although statistically significant, the odds ratios were small. However, despite these limitations, we 
analysed numerous cardiovascular risk factors and demonstrated associations of these factors with RNFLDs that 
could increase understanding of the pathogenesis of RNFLDs. The association of RNFLDs and cardiovascular risk 
factors should be considered when evaluating patients with RNFLDs. This association might have an impact on 
studies in glaucoma that use RNFLD as a diagnostic criterion; however, investigation of this was beyond the scope 
of our study because we excluded subjects with significant glaucomatous changes at the optic disc. We believe that 
future studies should investigate this possibility.
In conclusion, our findings indicate that localised RNFLDs are associated with certain cardiovascular risk 
factors, including SBP, eGFR, and HbA1c, suggesting that concomitant cardiovascular risk factors should be con-
sidered when evaluating a patient with localised RNFLDs.
Methods
Study populations. The Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
College of Medicine, has been enrolling subjects in the CMERC-HI cohort (ClinicalTrials.gov identifier 
NCT02003781) since December 2013. The study protocol will be reported in detail elsewhere. This study was 
performed in accordance with the tenets of the Declaration of Helsinki. The Institutional Review Board at 
Yonsei University approved the protocol for the present study (4-2014-000) and all participants provided written 
informed consent.
Subjects are deemed to have cardiovascular risk factors and enrolled in the CMERC-HI cohort study if they 
have any of the following: high-risk hypertension (eGFR >60 mL/min/1.73 m2 with damage to at least one target 
organ or an eGFR ≤60 mL/min/1.73 m2); DM with albuminuria; anuric end-stage renal disease requiring dialysis; 
a relative who sustained an acute myocardial infarction when aged younger than 55 years (if male) or 65 years (if 
female); asymptomatic atherosclerotic disease (abdominal aorta diameter ≥3 cm or ankle-brachial index >0.9, 
carotid plaque or carotid intima-media thickness ≥0.9 mm, an asymptomatic old cerebrovascular accident, or 
>30% stenosis in at least one major coronary artery); rheumatoid arthritis, age >40 years, and taking metho-
trexate and steroids; atrial fibrillation with a CHA2DS-VASc score ≥1; and a history of kidney transplantation 
more than 3 months beforehand. Subjects aged >20 years who met at least one inclusion criterion were enrolled 
in our present study. We excluded subjects with any of the following: acute myocardial infarction, acute coronary 
syndrome, or symptomatic coronary artery disease, or a history of any of these diseases; symptomatic peripheral 
artery disease or heart failure, or a history of either of these diseases; expected survival of less than 6 months for 
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a non-cardiovascular reason (e.g., cancer or sepsis); history of contrast allergy or side effects related to contrast 
materials; and current pregnancy or lactation.
In this study, we analysed the baseline data for 1508 subjects enrolled in the CMERC-HI cohort between 
November 2013 and June 2016 who agreed to an examination of the fundus.
Assessment of cardiovascular risk factors. Subjects underwent a standardised interview that included 
questions about a known diagnosis of hypertension, DM, and chronic kidney disease, as well as the current 
treatment of these diseases. Anthropometric parameters, including body height and weight, were measured. The 
HbA1c level and blood glucose, lipid, blood urea nitrogen, creatinine, and urinary albumin concentrations were 
measured in blood samples taken after fasting overnight and spot urine specimens. SBP and DBP were measured 
at 30-min intervals while subjects performed their normal daily activities, including sleep, using a 24-h ambula-
tory BP monitor (TM-2430, A & D Medical, Tokyo, Japan).
Predicted 10-year risk for atherosclerotic cardiovascular disease. ASCVD is defined as a nonfa-
tal myocardial infarction (heart attack), death from coronary heart disease, or stroke. The American College 
of Cardiology/American Heart Association (ACC/AHA) 2013 Pooled Cohort Equations formula estimates the 
10-year risk of ASCVD in patients who have never experienced one of these events in the past based on the 
covariates of age, treated or untreated systolic BP level, total cholesterol and high-density lipoprotein cholesterol 
levels, current smoking status (yes/no), and history of diabetes (yes/no)25. Using this formula, the ASCVD risk 
score was calculated and compared between subjects with and without RNFLDs. One hundred and four of 1508 
subjects were excluded from the analysis for being aged younger than 40 years or older than 80 years (ASCVD 
risk score not applicable; n = 94) or having a total cholesterol level <100 despite being within the appropriate age 
range (n = 10).
Retinal imaging with fundus photography and spectral-domain OCT. All subjects underwent fun-
dus photography and spectral-domain optical coherence tomography (OCT) on the same day. For both exami-
nations, the pupils were dilated using tropicamide 1%. Two fundus photographs of each eye, the first centred on 
the optic disc and the second centred on the fovea, were acquired using a 45° fundus camera (VisucamNM/FA, Carl 
Zeiss Meditec, Jena, Germany). Spectral-domain OCT (Spectralis HRA HROCT; Heidelberg Engineering GmbH, 
Dossenheim, Germany) was used to obtain circular scans (3.4 mm in diameter) centred at the optic disc and hori-
zontal, vertical-B, and volume scans of the macular area. The volume scans contained 49 sections (with spacing of 
120 μm) of a 20 × 20° area of the macula. Bilateral fundus photographs and OCT images were available for 1503 
of the 1508 subjects (5 subjects underwent examination of the fundus of only one eye because of media opacity).
A localised RNFLD was defined as a dark wedge-shaped area with a connecting optic disc border on fundus 
photography that had a width or length of 5°–45°9,26, which was confirmed on OCT as an abruptly dropped con-
tour line on the RNFL thickness profile (Fig. 1). The images of the fundus were assessed by an ophthalmologist 
(JYS) who was blinded to all subject data except for the fundus photographs and OCT images. To determine the 
inter-observer variability, photographs of 100 randomly selected subjects were reviewed by two blinded oph-
thalmologists (JYS, SHB) working independently of each other. The coefficient for inter-observer variability in 
detection of localised RNFLDs was 0.99. RNFLDs associated with significant glaucomatous changes at the optic 
disc, chorioretinal scarring, a history of uveitis, or retinal artery or vein occlusion were not regarded as localised 
RNFLDs in the analysis.
Figure 1. Localised retinal nerve fibre layer defect assessed using fundus photography (a) and spectral-domain 
optical coherence tomography (b). A localised retinal nerve fibre layer defect was defined as a dark wedge-
shaped area with a connecting optic disc border on fundus photography that had a width or length of 5°–45°  
(a), which was confirmed on optical coherence tomography as an abruptly dropped contour line on the 
thickness profile of the retinal nerve fibre layer (b).
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Statistical analysis. The independent t-test was used for continuous variables and the chi-squared test for 
categorical variables when comparing the baseline characteristics of the subject groups with and without RNFLs. 
Multivariate logistic regression was used to determine the association between presence of RNFLDs and cardio-
vascular risk factors. ORs and 95% CIs were calculated. In multivariate logistic regression, we used the presence 
of RNFLDs as a dependent variable. Parameters that were significantly associated with RNFLDs in the univariate 
analysis and were clinically significant were used as independent variables. Therefore, subjects with higher values 
for one or more independent variables (e.g., systolic pressure) had higher odds of having RNFLDs. In subjects 
with RNFLDs, the number of RNFLDs was regarded as the number of RNFLDs in the eyes with more RNFLDs. 
The Pearson correlation test was performed to determine the correlation between the number of RNFLDs and 
cardiovascular risk factors. The ASCVD risk score was compared between the groups with and without RNFLDs 
using the independent t-test. Given that age had a strong influence on the ASCVD risk score, we divided the 
subjects into groups aged 40–59 years (the middle-aged group) and those aged 60–79 years (older group). The sta-
tistical analysis was performed using SPSS for Windows (version 21.0; IBM Corp., Armonk, NY). A p-value al0.05 
was considered statistically significant.
Data availability
All data generated or analysed during this study are included in this article.
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